Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02269111 · ClinicalTrials.gov registry record · NA
Quantitative MRI in Assessing Disease in Patients With Brain Tumors
A NA study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT02269111 is a NA study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 10 participants.
The verdict
NCT02269111, a NA study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
This pilot clinical trial studies quantitative magnetic resonance imaging (MRI) at 3 Tesla in assessing disease in patients with tumors that have spread to the brain (brain metastases). In addition to routine care brain imaging of the brain, this study will include advanced multiparametric MRI sequences to measure vascular, cellular, and molecular properties of the tumor. Performing extra scans during MRI provides more information about the metastases and may better predict treatment response.
Interventions
- PROCEDURE diffusion-weighted magnetic resonance imaging
- PROCEDURE dynamic contrast-enhanced magnetic resonance imaging
- PROCEDURE chemical exchange saturation transfer magnetic resonance imaging
- PROCEDURE dynamic susceptibility contrast-enhanced magnetic resonance imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02269111
The ClinicalTrials.gov registry entry for NCT02269111 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which diffusion-weighted magnetic resonance imaging is the first listed.
NCT02269111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02269111 about?
NCT02269111 is a clinical study titled "Quantitative MRI in Assessing Disease in Patients With Brain Tumors". This pilot clinical trial studies quantitative magnetic resonance imaging (MRI) at 3 Tesla in assessing disease in patients with tumors that have spread to the brain (brain metastases). In addition to routine care brain imaging of the brain, this study will include advanced multiparametric MRI seque...
What is the current status of trial NCT02269111?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2015-04. Estimated completion is 2018-05.
What interventions are being tested in trial NCT02269111?
The interventions under investigation include: diffusion-weighted magnetic resonance imaging (PROCEDURE), dynamic contrast-enhanced magnetic resonance imaging (PROCEDURE), chemical exchange saturation transfer magnetic resonance imaging (PROCEDURE), dynamic susceptibility contrast-enhanced magnetic resonance imaging (PROCEDURE).
Who is sponsoring clinical trial NCT02269111?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.